Safeguard Scientifics, Inc. SFES
- Market cap
- $7.5M
- P/E
- 0.4×
Follow SFES
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.60 | 10.65 | 7.98 | 8.36 | 4.43 | 5.95 | 2.95 | 0.76 | 0.40 | 0.65 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 14.75 | 14.40 | 13.95 | 12.91 | 11.11 | 8.98 | 7.53 | 3.25 | 1.14 | 0.99 |
High Price
|
|||
| 33 | 33 | — | — | — | — | — | — | — | — |
Employees
|
|||
| 0 | 0 | — | — | — | — | — | — | — | — |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Gross Margin
|
|||
| (22) | (89) | (16) | 55 | (38) | 27 | (14) | (10) | (10) | 2 |
EBT
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| (22) | (89) | (16) | 55 | (38) | 27 | (14) | (10) | (10) | 2 |
Net Income
|
|||
| 2 | 3 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| (1.09) | (4.34) | (0.76) | 2.64 | (1.81) | 1.36 | (0.87) | (0.61) | (0.62) | 0.10 |
Earnings/Sh
|
|||
| (0.92) | (1.02) | (1.27) | (0.97) | (0.39) | (0.41) | (0.20) | (0.20) | (0.18) | (0.11) |
Cash Flow/Sh
|
|||
| (0.02) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
Capex/Sh
|
|||
| (0.94) | (1.02) | (1.27) | (0.97) | (0.39) | (0.41) | (0.20) | (0.20) | (0.17) | (0.11) |
Free CF/Sh
|
|||
| 8.35 | 4.00 | 3.26 | 4.93 | 3.03 | 2.55 | 2.12 | 1.23 | 0.59 | 0.69 |
Book Value/Sh
|
|||
| 20 | 20 | 21 | 21 | 21 | 20 | 16 | 16 | 17 | 17 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| (19) | (21) | (26) | (20) | (8) | (8) | (3) | (3) | (3) | (2) |
Op' Cash Flow
|
|||
| 0 | — | 0 | — | — | — | — | — | 0 | — |
Capex
|
|||
| (19) | (21) | (26) | (20) | (8) | (8) | (3) | (3) | (3) | (2) |
FCF
|
|||
| 27 | (12) | 14 | 24 | 13 | 29 | 20 | 8 | 6 | 8 |
Working Cap'
|
|||
| 53 | 86 | 70 | 3 | 2 | 2 | 2 | — | — | — |
Total Debt
|
|||
| 22 | 57 | 24 | (22) | (13) | (23) | (18) | (10) | (7) | (9) |
Net Debt
|
|||
| 170 | 82 | 67 | 102 | 63 | 51 | 35 | 20 | 10 | 12 |
Sh' Equity
|
|||
| (9.11%) | (43.39%) | (9.70%) | 43.08% | (42.60%) | 43.89% | (31.10%) | (32.47%) | (60.84%) | 14.48% |
ROA
|
|||
| (6.09%) | (7.72%) | (11.59%) | (7.85%) | (11.91%) | (16.05%) | (17.62%) | (33.95%) | (54.53%) | (50.98%) |
ROIC
|
|||
| (12.19%) | (70.41%) | (21.01%) | 64.68% | (45.70%) | 47.61% | (33.50%) | (36.03%) | (69.68%) | 16.14% |
ROE
|
|||
Safeguard Scientifics, Inc. peers in Asset Management
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CWD CaliberCos Inc. | $7.2M | 0.0× | Compare |
| ALP Alpha Compute Corp | $8.5M | 0.0× | Compare |
| TWAV TaoWeave, Inc. | $6.2M | 0.0× | Compare |
| BNKK Bonk, Inc. | $12.0M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| JP Jupai Holdings Limited | $12.1M | 0.0× | Compare |
| ICMB Investcorp Credit Management BDC, Inc. | $12.4M | 0.0× | Compare |
| EQS Equus Total Return, Inc. | $13.3M | 0.0× | Compare |
| BCG Binah Capital Group, Inc. | $19.9M | 5.8× | Compare |
Safeguard Scientifics, Inc. (SFES) key facts
- Safeguard Scientifics, Inc. (SFES) is an Asset Management company in the Financial sector.
- Net income was $1.7 million, or $0.10 per share (basic), a net margin of 0.00%.
- As of September 25, 2026, SFES traded at $0.41, a market capitalization of $7.5 million.
- At that price the stock trades at 0.4× trailing-twelve-month earnings.
- Return on equity was 16.1% and debt-to-equity 0.00.
Safeguard Scientifics, Inc. (SFES) Latest News
14 Nov
Safeguard Scientifics, Inc. (SFES) reported its Q3 earnings, highlighting a notable increase in revenue compared to the previous quarter. The company attributed this growth to successful investments and strategic initiatives. However, expenses also rose, impacting overall profitability. Management expressed optimism about future prospects, citing ongoing projects and market opportunities. The earnings report reflects a mixed performance, with both positive revenue growth and challenges in cost management. Revenue growth indicates potential for improved financial performance, but rising expenses may limit overall profitability.
14 Aug
Safeguard Scientifics, Inc. (SFES) reported its Q2 earnings, highlighting a notable increase in revenue compared to the previous quarter. The company attributed this growth to successful investments and strategic partnerships. Despite challenges in the market, SFES remains optimistic about future performance, focusing on innovation and expanding its portfolio. The earnings report reflects a commitment to enhancing shareholder value and navigating industry dynamics effectively. The earnings report indicates moderate growth and strategic focus, which may positively influence financial performance but is balanced by market challenges.